The leukapheresis market involves the medical and biotechnology sector focused on devices, disposables, and services used to separate and collect white blood cells from a patient’s or donor’s bloodstream. It spans therapeutic applications for treating blood disorders and cancers, as well as the collection of high-quality starting materials for clinical research and advanced cell and gene therapies like CAR-T.
The global leukapheresis market was valued at USD 83.3 billion in 2025 and USD 90.6 billion in 2026, and it is projected to reach USD 138.7 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.9%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148
The leukapheresis market is primarily driven by the rising global prevalence of hematologic malignancies and autoimmune disorders, growing R&D investments, and the increasing adoption of personalized medicines such as CAR-T cell and gene therapies. However, market expansion is heavily restrained by the high cost of sophisticated apheresis devices and specialized single-use disposable kits, alongside severe shortages of skilled apheresis professionals. Lucrative opportunities exist in the rapid infrastructure modernization and regulatory acceleration within the Asia-Pacific region, rising demand for in-house collection capacity at commercial CAR-T plants, and the expanding utilization of leukopaks in clinical research. Despite these prospects, the market faces key challenges, including stringent global regulatory compliance frameworks for cross-border biologics movement, donor availability constraints, and operational bottlenecks related to the viability loss of harvested cells during long-distance cold-chain transport.
The target customers for the leukapheresis market comprise a diverse mix of clinical providers and research institutions, primarily dominated by hospitals, clinics, transplant centers, blood component providers, and academic and research institutes, alongside a rapidly growing segment of pharmaceutical, biotechnology, and contract manufacturing organizations (CDMOs). These customers require reliable, automated, and closed-system cell separation technologies to isolate high-purity leukocytes, stem cells, and high-quality starting materials like leukopaks essential for clinical research, drug development, and advanced cell and gene therapies such as CAR-T manufacturing. They demonstrate a strong preference for continuous-flow platforms equipped with advanced optical-detection sensors and integrated single-use tubing sets that minimize contamination risks, ensure donor safety, and accelerate processing throughput. Their purchasing behavior is characterized by high, recurring capital outlays for single-use disposables to support consistent procedure volumes, alongside strategic capital investments in high-margin automated devices and collaborative partnerships with regional blood centers to secure a reliable, compliant supply of specialized cellular materials.
Market entry, expansion, and profitability in the leukapheresis industry market are heavily shaped by stringent regulatory frameworks, rapid technological integration, and distinct economic pressures. Regulatory compliance requirements and approval pathways for complex medical devices and cell therapy collections remain strict, elevating operational standards but also increasing compliance costs for new entrants. Technologically, the market is being driven forward by the integration of automated continuous-flow centrifugation, closed-loop systems, real-time monitoring software, and optical-detection sensors that improve cell yield purity and donor safety while optimizing throughput. However, economic factors such as high upfront capital investment for specialized apheresis units, steep procedural costs for sterile disposable kits, and a global shortage of skilled medical professionals pose significant risks to long-term profitability and widespread adoption in resource-limited or price-sensitive regions.
The leukapheresis market is being profoundly shaped by the rapid expansion of cell and gene therapies, transitioning the procedure from an acute clinical intervention into an indispensable manufacturing component for CAR-T, TCR, and NK-cell immunotherapy programs. Current and emerging trends focus heavily on the adoption of automated, AI-assisted monitoring to optimize leukocyte yields, the development of centrifugation-free microfluidic cell separation technologies, and the rise of portable bedside units for point-of-care leukoreduction. These trends are evolving swiftly, highlighted by cell- and gene-therapy manufacturers internalizing collection capacity at a projected CAGR of 12.01% through 2031, while continuous-flow device upgrades drive a 10.37% CAGR for the equipment segment, altogether positioning the global market to reach up to USD 64.01 billion by 2031.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148
Technological innovations disrupting the leukapheresis industry market are centered on automation, precision cell separation, and enhanced patient safety, driven primarily by the integration of automated closed-loop apheresis systems that feature real-time monitoring and automated adjustments for critical parameters. The industry is witnessing significant traction in the adoption of artificial intelligence and advanced sensors to optimize flow rates, track pressure, and monitor leukocyte yields, thereby minimizing operator error and clinical workflow strain. Furthermore, advancements in filtration techniques, microfluidic cell separation technology enabling centrifugation-free methods for pediatric use, and standardized automated closed production systems for cryopreserved leukapheresis are rapidly expanding, paving the way for scalable, decentralized, and highly pure starting materials for CAR-T cell manufacturing and personalized immunotherapies.
In the leukapheresis industry market, short-term hype often surrounds temporary procurement spikes, episodic clinical trial adjustments, and early-stage experimental components that experience sudden interest but face fluctuating immediate demand. Conversely, long-term structural shifts are firmly anchored in advanced oncology infrastructure and the expansion of personalized medicine. These permanent changes include the accelerating commercialization of CAR-T and cell therapies, the widespread adoption of automated continuous-flow apheresis systems to improve throughput amid staffing shortages, and a steadily growing institutional demand for leukopaks in clinical research and targeted blood processing for hematologic disorders.
Source:https://www.marketsandmarkets.com/Market-Reports/leukapheresis-market-20283148.html
